Explore
Validate
Learn
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA055889 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA055889, RRID:AB_2682958
- Product name
- Anti-NFE2L3
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human NFE2L3, Gene description: nuclear factor, erythroid 2-like 3, Alternative Gene Names: Nrf3, Validated applications: ICC, Uniprot ID: Q9Y4A8, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5
NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma
MicroRNA-1246 Mediates Drug Resistance and Metastasis in Breast Cancer by Targeting NFE2L3
Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors
Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients
RCAN1-4 is a thyroid cancer growth and metastasis suppressor
Gurri S, Siegenthaler B, Cangkrama M, Restivo G, Huber M, Saliba J, Dummer R, Blank V, Hohl D, Werner S
EMBO Molecular Medicine 2023;15(11)
EMBO Molecular Medicine 2023;15(11)
NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma
Immonen A, Haapasaari K, Skarp S, Karihtala P, Teppo H, Bekeschus S
Oxidative Medicine and Cellular Longevity 2022;2022
Oxidative Medicine and Cellular Longevity 2022;2022
MicroRNA-1246 Mediates Drug Resistance and Metastasis in Breast Cancer by Targeting NFE2L3
Dai Y, Pan Y, Quan M, Chen Q, Pan Y, Ruan Y, Sun J
Frontiers in Oncology 2021;11
Frontiers in Oncology 2021;11
Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors
Kobayashi A
Cancers 2020;12(9):2681
Cancers 2020;12(9):2681
Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients
Wang H, Zhan M, Yang R, Shi Y, Liu Q, Wang J
Cell Cycle 2018;17(17):2164-2174
Cell Cycle 2018;17(17):2164-2174
RCAN1-4 is a thyroid cancer growth and metastasis suppressor
Wang C, Saji M, Justiniano S, Yusof A, Zhang X, Yu L, Fernández S, Wakely P, La Perle K, Nakanishi H, Pohlman N, Ringel M
JCI Insight 2017;2(5)
JCI Insight 2017;2(5)
No comments: Submit comment
No validations: Submit validation data